Story
Taysha Gene Therapies Stock Slides on Wider-Than-Expected Q2 Loss

Shares of Taysha Gene Therapies (NASDAQ: TSHA) fell more than 7% in morning trading after the company posted a wider-than-expected second-quarter loss. The sell-off was triggered by a significant jump in operating expenses that overshadowed the company's strong cash position and ongoing clinical progress.
Earnings Miss and Widening Losses
Taysha reported a net loss of $46.6 million, or $0.13 per share, for the second quarter. This missed the consensus analyst estimate of a $0.12 loss per share and marked a substantial increase from the $26.9 million net loss, or $0.09 per share, recorded in the same period a year ago.
The accelerating losses were driven by a sharp increase in spending across the company's operations. Key figures from the report include:
- Research and development (R&D) expenses: Rose to $38.6 million, an increase of $18.5 million year-over-year, due to activities related to its REVEAL and ASPIRE clinical trials.
- General and administrative (G&A) expenses: Climbed to $12.1 million from $8.6 million in the prior-year quarter, primarily from higher compensation and costs for commercial launch preparations.
AdMarket Context and Outlook
The decline in Taysha's stock was company-specific, occurring as the broader S&P 500 and Nasdaq indices both gained during the session. The negative reaction from investors came despite the company's solid financial footing.
Taysha ended the quarter with $455.4 million in cash and cash equivalents, bolstered by $230.0 million in gross proceeds from a follow-on financing in June. While the company noted its TSHA-102 therapy remains well-tolerated in clinical trials, the market's near-term focus has shifted to the pace of cash consumption ahead of anticipated regulatory milestones in 2027.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.